Valentina O. Puntmann

Valentina O. Puntmann

Auto-generated profile, based on publicly available information

Valentina O. Puntmann

DZHK Centre for Cardiovascular Imaging, Institute for Experimental and Translational Cardiovascular Imaging, German Centre for Cardiovascular Research – Partner Site Rhein-Main, Goethe University Frankfurt, Frankfurt am Main, Germany

Research Focus & Metrics

Academic Career Length

22Years (2005-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2013 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
VPValentina O. Puntmann
Valentina O. Puntmann
TVTobias Voigt
Tobias Voigt
ZCZhong Chen
Zhong Chen
MMManuel Mayr
Manuel Mayr
RKRashed Karim
Rashed Karim
ENEike Nagel
Eike Nagel

1 January 2016 in JACC: Cardiovascular Imaging
Verified
Journal Article
Closed access
VPValentina O. Puntmann
Valentina O. Puntmann
GCGerry Carr-White
Gerry Carr-White
AJAndrew Jabbour
Andrew Jabbour
CYChung-Yao Yu
Chung-Yao Yu
RGRolf Gebker
Rolf Gebker
ENEike Nagel
Eike Nagel

8 July 2016 in Circulation Research
Verified
Journal Article
Closed access
PDF file
VPValentina O. Puntmann
Valentina O. Puntmann
EPElif Peker
Elif Peker
YCY. Chandrashekhar
Y. Chandrashekhar
ENEike Nagel
Eike Nagel
Cardiovascular magnetic resonance provides insights into myocardial structure and function noninvasively, with high diagnostic accuracy and without ionizing radiation. Myocardial tissue characterization in particular gives cardiovascular magnetic resonance a prime role among all the noninvasive cardiovascular investigations. Late gadolinium enhancement imaging is an established method for visualizing replacement scar, providing diagnostic and prognostic information in a variety of cardiac conditions. Late gadolinium enhancement, however, relies on the regional segregation of tissue characteristics to generate the imaging contrast. Thus, myocardial pathology that is diffuse in nature and affecting the myocardium in a rather uniform and global distribution is not well visualized with late gadolinium enhancement. Examples include diffuse myocardial inflammation, fibrosis, hypertrophy, and infiltration. T1 mapping is a novel technique allowing to diagnose these diffuse conditions by measurement of T1 values, which directly correspond to variation in intrinsic myocardial tissue properties. In addition to providing clinically meaningful indices, T1-mapping measurements also allow for an estimation of extracellular space by calculation of extracellular volume fraction. Multiple lines of evidence suggest a central role for T1 mapping in detection of diffuse myocardial disease in early disease stages and complements late gadolinium enhancement in visualization of the regional changes in common advanced myocardial disease. As a quantifiable measure, it may allow grading of disease activity, monitoring progress, and guiding treatment, potentially as a fast contrast-free clinical application. We present an overview of clinically relevant technical aspects of acquisition and processing, and the current state of art and evidence, supporting its clinical use.

21 October 2014 in Journal of Cardiovascular Magnetic Resonance
Verified
Journal Article
Open access
PDF file
DDDarius Dabir
Darius Dabir
NCNicholas Child
Nicholas Child
AKAshwin Kalra
Ashwin Kalra
TRToby Rogers
Toby Rogers
RGRolf Gebker
Rolf Gebker
VPValentina O Puntmann
Valentina O Puntmann
T1 mapping is a robust and highly reproducible application to quantify myocardial relaxation of longitudinal magnetisation. Available T1 mapping methods are presently site and vendor specific, with variable accuracy and precision of T1 values between the systems and sequences. We assessed the transferability of a T1 mapping method and determined the reference values of healthy human myocardium in a multicenter setting. Healthy subjects (n = 102; mean age 41 years (range 17–83), male, n = 53 (52%)), with no previous medical history, and normotensive low risk subjects (n=113) referred for clinical cardiovascular magnetic resonance (CMR) were examined. Further inclusion criteria for all were absence of regular medication and subsequently normal findings of routine CMR. All subjects underwent T1 mapping using a uniform imaging set-up (modified Look- Locker inversion recovery, MOLLI, using scheme 3(3)3(3)5)) on 1.5 Tesla (T) and 3 T Philips scanners. Native T1-maps were acquired in a single midventricular short axis slice and repeated 20 minutes following gadobutrol. Reference values were obtained for native T1 and gadolinium-based partition coefficients, λ and extracellular volume fraction (ECV) in a core lab using standardized postprocessing. In healthy controls, mean native T1 values were 950 ± 21 msec at 1.5 T and 1052 ± 23 at 3 T. λ and ECV values were 0.44 ± 0.06 and 0.25 ± 0.04 at 1.5 T, and 0.44 ± 0.07 and 0.26 ± 0.04 at 3 T, respectively. There were no significant differences between healthy controls and low risk subjects in routine CMR parameters and T1 values. The entire cohort showed no correlation between age, gender and native T1. Cross-center comparisons of mean values showed no significant difference for any of the T1 indices at any field strength. There were considerable regional differences in segmental T1 values. λ and ECV were found to be dose dependent. There was excellent inter- and intraobserver reproducibility for measurement of native septal T1. We show transferability for a unifying T1 mapping methodology in a multicenter setting. We provide reference ranges for T1 values in healthy human myocardium, which can be applied across participating sites.

1 December 2015 in Circulation: Cardiovascular Imaging
Verified
Journal Article
Closed access
PDF file
RHRocio Hinojar
Rocio Hinojar
NVNiharika Varma
Niharika Varma
NCNick Child
Nick Child
BGBenjamin Goodman
Benjamin Goodman
AJAndrew Jabbour
Andrew Jabbour
VPValentina O. Puntmann
Valentina O. Puntmann
Background—: The differential diagnosis of left ventricular (LV) hypertrophy remains challenging in clinical practice, in particular, between hypertrophic cardiomyopathy (HCM) and increased LV wall thickness because of systemic hypertension. Diffuse myocardial disease is a characteristic feature in HCM, and an early manifestation of sarcomere–gene mutations in subexpressed family members (G+P− subjects). This study aimed to investigate whether detecting diffuse myocardial disease by T1 mapping can discriminate between HCM versus hypertensive heart disease as well as to detect genetically driven interstitial changes in the G+P− subjects. Methods and Results—: Patients with diagnoses of HCM or hypertension (HCM, n=95; hypertension, n=69) and G+P− subjects (n=23) underwent a clinical cardiovascular magnetic resonance protocol (3 tesla) for cardiac volumes, function, and scar imaging. T1 mapping was performed before and >20 minutes after administration of 0.2 mmol/kg of gadobutrol. Native T1 and extracellular volume fraction were significantly higher in HCM compared with patients with hypertension ( P 15 mm ( P <0.0001). Compared with controls, native T1 was significantly higher in G+P− subjects ( P 2 SD above the mean of the normal range. Native T1 was an independent discriminator between HCM and hypertension, over and above extracellular volume fraction, LV wall thickness and indexed LV mass. Native T1 was also useful in separating G+P− subjects from controls. Conclusions—: Native T1 may be applied to discriminate between HCM and hypertensive heart disease and detect early changes in G+P− subjects.

14 February 2012 in Circulation
Verified
Journal Article
Closed access
JBJavier Barallobre-Barreiro
Javier Barallobre-Barreiro
ADAthanasios Didangelos
Athanasios Didangelos
FSFriedrich A. Schoendube
Friedrich A. Schoendube
IDIgnat Drozdov
Ignat Drozdov
XYXiaoke Yin
Xiaoke Yin
MMManuel Mayr
Manuel Mayr
Background—: After myocardial ischemia, extracellular matrix (ECM) deposition occurs at the site of the focal injury and at the border region. Methods and Results—: We have applied a novel proteomic method for the analysis of ECM in cardiovascular tissues to a porcine model of ischemia/reperfusion injury. ECM proteins were sequentially extracted and identified by liquid chromatography tandem mass spectrometry. For the first time, ECM proteins such as cartilage intermediate layer protein 1, matrilin-4, extracellular adipocyte enhancer binding protein 1, collagen α-1(XIV), and several members of the small leucine-rich proteoglycan family, including asporin and prolargin, were shown to contribute to cardiac remodeling. A comparison in 2 distinct cardiac regions (the focal injury in the left ventricle and the border region close to the occluded coronary artery) revealed a discordant regulation of protein and mRNA levels; although gene expression for selected ECM proteins was similar in both regions, the corresponding protein levels were much higher in the focal lesion. Further analysis based on >100 ECM proteins delineated a signature of early- and late-stage cardiac remodeling with transforming growth factor-β1 signaling at the center of the interaction network. Finally, novel cardiac ECM proteins identified by proteomics were validated in human left ventricular tissue acquired from ischemic cardiomyopathy patients at cardiac transplantation. Conclusion—: Our findings reveal a biosignature of early- and late-stage ECM remodeling after myocardial ischemia/reperfusion injury, which may have clinical utility as a prognostic marker and modifiable target for drug discovery.